Radioimmunotherapy in colorectal cancer treatment: present and future
Colorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational and effective treatment remains a major challenge. Common treatments include multi-modal combinations of surgery, radiotherapy,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105180/full |
| _version_ | 1797829990755074048 |
|---|---|
| author | Jingyi Shi Zhuang Sun Zhaoya Gao Zhaoya Gao Dandan Huang Haopeng Hong Jin Gu Jin Gu Jin Gu |
| author_facet | Jingyi Shi Zhuang Sun Zhaoya Gao Zhaoya Gao Dandan Huang Haopeng Hong Jin Gu Jin Gu Jin Gu |
| author_sort | Jingyi Shi |
| collection | DOAJ |
| description | Colorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational and effective treatment remains a major challenge. Common treatments include multi-modal combinations of surgery, radiotherapy, and chemotherapy; however, recurrence and metastasis rates remain high. The combination of radiotherapy and immunotherapy (radioimmunotherapy [RIT]) may offer new solutions to this problem, but its prospects remain uncertain. This review aimed to summarize the current applications of radiotherapy and immunotherapy, elaborate on the underlying mechanisms, and systematically review the preliminary results of RIT-related clinical trials for CRC. Studies have identified several key predictors of RIT efficacy. Summarily, rational RIT regimens can improve the outcomes of some patients with CRC, but current study designs have limitations. Further studies on RIT should focus on including larger sample sizes and optimizing the combination therapy regimen based on underlying influencing factors. |
| first_indexed | 2024-04-09T13:30:02Z |
| format | Article |
| id | doaj.art-d8296b82d8a640119199773e16dcf62d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T13:30:02Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d8296b82d8a640119199773e16dcf62d2023-05-10T05:13:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11051801105180Radioimmunotherapy in colorectal cancer treatment: present and futureJingyi Shi0Zhuang Sun1Zhaoya Gao2Zhaoya Gao3Dandan Huang4Haopeng Hong5Jin Gu6Jin Gu7Jin Gu8Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, Beijing, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, Beijing, ChinaDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, ChinaDepartment of General Surgery, Peking University First Hospital, Beijing, ChinaDepartment of Oncology, Peking University Shougang Hospital, Beijing, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, Beijing, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, Beijing, ChinaDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, ChinaPeking Tsinghua Center for Life Science, Peking University International Cancer Center, Beijing, ChinaColorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational and effective treatment remains a major challenge. Common treatments include multi-modal combinations of surgery, radiotherapy, and chemotherapy; however, recurrence and metastasis rates remain high. The combination of radiotherapy and immunotherapy (radioimmunotherapy [RIT]) may offer new solutions to this problem, but its prospects remain uncertain. This review aimed to summarize the current applications of radiotherapy and immunotherapy, elaborate on the underlying mechanisms, and systematically review the preliminary results of RIT-related clinical trials for CRC. Studies have identified several key predictors of RIT efficacy. Summarily, rational RIT regimens can improve the outcomes of some patients with CRC, but current study designs have limitations. Further studies on RIT should focus on including larger sample sizes and optimizing the combination therapy regimen based on underlying influencing factors.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105180/fullcolorectal cancerradiotherapyimmunotherapymetastasislocally advanced rectal cancer |
| spellingShingle | Jingyi Shi Zhuang Sun Zhaoya Gao Zhaoya Gao Dandan Huang Haopeng Hong Jin Gu Jin Gu Jin Gu Radioimmunotherapy in colorectal cancer treatment: present and future Frontiers in Immunology colorectal cancer radiotherapy immunotherapy metastasis locally advanced rectal cancer |
| title | Radioimmunotherapy in colorectal cancer treatment: present and future |
| title_full | Radioimmunotherapy in colorectal cancer treatment: present and future |
| title_fullStr | Radioimmunotherapy in colorectal cancer treatment: present and future |
| title_full_unstemmed | Radioimmunotherapy in colorectal cancer treatment: present and future |
| title_short | Radioimmunotherapy in colorectal cancer treatment: present and future |
| title_sort | radioimmunotherapy in colorectal cancer treatment present and future |
| topic | colorectal cancer radiotherapy immunotherapy metastasis locally advanced rectal cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105180/full |
| work_keys_str_mv | AT jingyishi radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT zhuangsun radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT zhaoyagao radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT zhaoyagao radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT dandanhuang radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT haopenghong radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT jingu radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT jingu radioimmunotherapyincolorectalcancertreatmentpresentandfuture AT jingu radioimmunotherapyincolorectalcancertreatmentpresentandfuture |